Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4449880
Max Phase: Preclinical
Molecular Formula: C69H107N17O12S
Molecular Weight: 1398.79
Molecule Type: Unknown
Associated Items:
ID: ALA4449880
Max Phase: Preclinical
Molecular Formula: C69H107N17O12S
Molecular Weight: 1398.79
Molecule Type: Unknown
Associated Items:
Canonical SMILES: CSCC[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(=N)N)N(C)C(=O)[C@H](N)CCCCN)C(C)C)C(C)C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)O
Standard InChI: InChI=1S/C69H107N17O12S/c1-41(2)57(65(94)79-51(31-36-99-6)60(89)82-55(39-45-40-77-49-23-11-10-21-47(45)49)62(91)78-50(24-13-16-33-71)59(88)80-52(68(97)98)25-14-17-34-72)85-66(95)58(42(3)4)84-63(92)54(38-44-27-29-46(87)30-28-44)81-61(90)53(37-43-19-8-7-9-20-43)83-64(93)56(26-18-35-76-69(74)75)86(5)67(96)48(73)22-12-15-32-70/h7-11,19-21,23,27-30,40-42,48,50-58,77,87H,12-18,22,24-26,31-39,70-73H2,1-6H3,(H,78,91)(H,79,94)(H,80,88)(H,81,90)(H,82,89)(H,83,93)(H,84,92)(H,85,95)(H,97,98)(H4,74,75,76)/t48-,50+,51+,52-,53+,54+,55+,56+,57+,58+/m1/s1
Standard InChI Key: XLGLSJQWSFFJAY-VYWRNTLYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1398.79 | Molecular Weight (Monoisotopic): 1397.8006 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Denèfle T, Pramil E, Gómez-Morales L, Levasseur MD, Lardé E, Newton C, Herry K, Herbi L, Lamotte Y, Odile E, Ancellin N, Grondin P, Martinez-Torres AC, Viviani F, Merle-Beral H, Lequin O, Susin SA, Karoyan P.. (2019) Homotrimerization Approach in the Design of Thrombospondin-1 Mimetic Peptides with Improved Potency in Triggering Regulated Cell Death of Cancer Cells., 62 (17): [PMID:31403795] [10.1021/acs.jmedchem.9b00024] |
Source(1):